metaOBS - - Real World Evidence KB

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament	Trials	Summary Endpoints
Treament	Trials	clinical improvement	clinical worsening	deaths	PCR-negative conversion
proton pump inhibitors	3	-	OBS 1.95 [1.33; 2.87], 2 studies, I2=0% statistically significant harm	OBS 1.20 [0.11; 12.56], 2 studies, I2=91% inconclusive result	-
alpha lipoic acid	1	-	-	0.17 [0.02; 1.44], 1 RCT, I2=0% inconclusive result	-
acetylcysteine	0	-	-	-	-
aviptadil	0	-	-	-	-
bevacizumab	0	-	-	-	-
bismuth	0	-	-	-	-
BLD-2660 (calpain inhibitor)	0	-	-	-	-
calcium channel blocker	0	-	-	-	-
camostat mesilate	0	-	-	-	-
continuous positive airway pressure (CPAP)	0	-	-	-	-
cytokine adsorption	0	-	-	-	-
diammonium glycyrrhizinate	0	-	-	-	-
dipyridamol	0	-	-	-	-
DPP-4 inhibitor	0	-	-	-	-
enoxaparin	0	-	-	-	-
kinin-kallikrein inhibitors	0	-	-	-	-
levamisole	0	-	-	-	-
metformin	0	-	-	-	-
natural killer (NK) cells	0	-	-	-	-
nicotin	0	-	-	-	-
nitric oxide (gas Inhalation or releasing solution)	0	-	-	-	-
ozonated autohemotherapy	0	-	-	-	-
pamrevlumab	0	-	-	-	-
povidone-iodine	0	-	-	-	-
PUL-042 inhalation solution	0	-	-	-	-
selinexor	0	-	-	-	-
statins	0	-	-	-	-
stem cells	0	-	-	-	-
tradipitant	0	-	-	-	-
tranilast	0	-	-	-	-